Royalty Pharma plc Files 8-K for Operations Update

Ticker: RPRX · Form: 8-K · Filed: May 8, 2025 · CIK: 1802768

Royalty Pharma PLC 8-K Filing Summary
FieldDetail
CompanyRoyalty Pharma PLC (RPRX)
Form Type8-K
Filed DateMay 8, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting, operations

TL;DR

Royalty Pharma filed an 8-K on May 8th, standard ops and financials update.

AI Summary

Royalty Pharma plc filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event.

Why It Matters

This filing serves as a public notification of significant corporate events or financial updates for Royalty Pharma plc, allowing investors and the market to stay informed.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for reporting operational and financial information, not indicating any specific negative events.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific financial figures.

When was this 8-K filing submitted?

The filing was submitted on May 8, 2025.

What is the principal executive office address for Royalty Pharma plc?

The principal executive office is located at 110 East 59th Street, New York, New York, 10022.

What is the company's telephone number?

The company's telephone number is (212) 883-0200.

What is the SIC code for Royalty Pharma plc?

The Standard Industrial Classification (SIC) code for Royalty Pharma plc is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Royalty Pharma plc (RPRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing